Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018

March 2018 | 66 pages | ID: M2894EFD6A5EN
Global Markets Direct

Abstracts

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018

SUMMARY

According to the recently published report 'Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018'; Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake.

The report 'Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018' outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 4 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.

Report covers products from therapy areas Metabolic Disorders, Musculoskeletal Disorders, Women's Health, Central Nervous System, Genetic Disorders, Infectious Disease and Male Health which include indications Obesity, Type 2 Diabetes, Alphavirus Infections, Amyotrophic Lateral Sclerosis, Cachexia, Diabetes, Erectile Dysfunction, Female Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, Gouty Arthritis (Gout), Lipodystrophy, Metabolic Syndrome and Prader-Willi Syndrome (PWS).

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)
• The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects
• The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
Melanocortin Receptor 4 (MC4R) - Overview
Melanocortin Receptor 4 (MC4R) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development
AstraZeneca Plc
MallInckrodt Plc
Palatin Technologies Inc
Melanocortin Receptor 4 (MC4R) - Drug Profiles
(liraglutide + setmelanotide) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AQB-565 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bremelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
corticotropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-8905 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
setmelanotide ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize MC4-R for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female Sexual Dysfunction and Erectile Dysfunction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Melanocortin Receptor 4 (MC4R) - Dormant Products
Melanocortin Receptor 4 (MC4R) - Discontinued Products
Melanocortin Receptor 4 (MC4R) - Product Development Milestones
Featured News & Press Releases
Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis
Jan 04, 2018: Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity
Dec 04, 2017: Mallinckrodt plc Presents Health Economic Data on Management of Infantile Spasms at American Epilepsy Society Annual Meeting
Oct 31, 2017: Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome
Oct 26, 2017: Mallinckrodt Presents Multiple Sclerosis Relapse Data at 7th Joint ECTRIMS-ACTRIMS Meeting (MSParis2017)
Oct 09, 2017: Mallinckrodt Statement on October 7, 2017, CHEST Journal Article
Oct 09, 2017: Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis
Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters
Jul 31, 2017: Summary Review of Clinical and Economic Data on H.P. Acthar Gel Published in Advances in Therapy
Jul 25, 2017: Mallinckrodt Posts Data From Legacy H.P. Acthar Gel (Repository Corticotropin Injection) Pilot Study To clinicaltrials.gov
Jun 27, 2017: Rhythm and Camurus Announce Positive Initial Data for Extended-Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of Obesity
Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert
Jun 22, 2017: Mallinckrodt Statement on H.P. Acthar Gel Update
Jun 14, 2017: Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis
Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by MallInckrodt Plc, H1 2018
Pipeline by Palatin Technologies Inc, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd..1), H1 2018
Discontinued Products, H1 2018

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018

COMPANIES MENTIONED

AstraZeneca Plc
MallInckrodt Plc
Palatin Technologies Inc